Allogene Therapeutics, Inc. Common Stock

ALLONASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
2.04 USD
↘ 0.13 (5.99%)AT CLOSE (11:59 AM EDT)
2.05
↗ 0.01 (0.25%)
POST MARKET (AS OF 07:51 PM EDT)
Post Market
AS OF 07:51 PM EDT
2.05
↗ 0.01 (0.25%)
🔴Market: CLOSED

Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $2.03 per share. ALLO shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, ALLO trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 26, 2026.

Open?$2.17
High?$2.18
Low?$2.03
Prev. Close?$2.17
Volume?5.0M
Avg. Volume?5.7M
VWAP?$2.06
Rel. Volume?0.89x
Bid / Ask
Bid?$2.04 × 200
Ask?$2.05 × 2.0K
Spread?$0.01
Midpoint?$2.05
Valuation & Ratios
Market Cap?704.8M
Shares Out?345.5M
Float?170.0M
Float %?69.4%
P/E Ratio?N/A
P/B Ratio?1.62
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
152
Market Cap
749.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.allogene.com
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.02Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?34.68%Squeeze Risk
Short Interest?58.9M
Days to Cover?11.9
Free Float170.0M
Avg Daily Volume4.9M
Settlement Date2026-08-14
Financial Health
Current Ratio?10.72Strong
Quick Ratio?10.72Strong
Cash Ratio?1.22Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
84
1.62CHEAP▾
P/S?
Peers
100
S&P
3
151.90HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
143.57HIGH▾
Returns & Efficiency
ROE?
S&P
3
-37.9%WEAK▾
ROA?
S&P
3
-30.1%WEAK▾
Cash Flow & Enterprise
FCF?$-102598000
Enterprise Value?$666.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist